PMID- 30662306
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231005
IS  - 1319-0164 (Print)
IS  - 2213-7475 (Electronic)
IS  - 1319-0164 (Linking)
VI  - 27
IP  - 1
DP  - 2019 Jan
TI  - Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and 
      cytotoxicity.
PG  - 49-55
LID - 10.1016/j.jsps.2018.07.018 [doi]
AB  - OBJECTIVE: The aim of the present study was to formulate the anticancer drug; 
      docetaxel (DOX) as nanoparticles to enhance its biological activity. METHODOLOGY: 
      Solvent precipitation method was used to prepare DOX-loaded nanoparticles and was 
      stabilized by different concentrations of hydroxypropyl methylcellulose (HPMC, 
      E5) and sodium deoxycholate (SDC). RESULTS: The results showed that the particle 
      size of the prepared DOX nanoparticles stabilized by SDC was small in comparison 
      to those stabilized by the corresponding HPMC concentrations. The smallest 
      particle size (83.97 nm) was obtained by using SDC as stabilizer at 5% level with 
      zeta potential of -13.6 mV. It was concluded that increasing the stabilizer 
      concentration resulted in increase in both initial and overall cumulative drug 
      release. The release rate in case of nanoparticles stabilized by 5% SDC was 33% 
      and 87% after 1 and 24 h respectively. The results showed that a significant 
      reduction in the viability of FRO cells was observed at all tested time intervals 
      in case of nanoparticles stabilized by 5% SDC at concentrations of 100 and 
      1000 muM/ml. In contrast, no signs of cytotoxicity was observed for nanoparticles 
      stabilized by 5% HPMC at 10 and 100 muM/ml concentrations.
FAU - Ibrahim, Mohamed A
AU  - Ibrahim MA
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 
      2457, Riyadh 11451, Saudi Arabia.
AD  - Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, 
      Al-Azhar University, Assiut, Egypt.
FAU - Shazly, Gamal A
AU  - Shazly GA
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 
      2457, Riyadh 11451, Saudi Arabia.
AD  - Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, 
      Assiut, Egypt.
FAU - Aleanizy, Fadilah S
AU  - Aleanizy FS
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 
      2457, Riyadh 11451, Saudi Arabia.
FAU - Alqahtani, Fulwah Y
AU  - Alqahtani FY
AD  - Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 
      2457, Riyadh 11451, Saudi Arabia.
FAU - Elosaily, Gehan M
AU  - Elosaily GM
AD  - Department of Pathology, Faculty of Medicine, Almareffa College for Science and 
      Technology, Riyadh, Saudi Arabia.
AD  - Department of Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt.
LA  - eng
PT  - Journal Article
DEP - 20180720
PL  - Saudi Arabia
TA  - Saudi Pharm J
JT  - Saudi pharmaceutical journal : SPJ : the official publication of the Saudi 
      Pharmaceutical Society
JID - 9705695
PMC - PMC6323146
OTO - NOTNLM
OT  - Cytotoxicity
OT  - Docetaxel
OT  - In-vitro release
OT  - Nanoparticles
OT  - Stabilizers
EDAT- 2019/01/22 06:00
MHDA- 2019/01/22 06:01
PMCR- 2018/07/20
CRDT- 2019/01/22 06:00
PHST- 2018/04/22 00:00 [received]
PHST- 2018/07/19 00:00 [accepted]
PHST- 2019/01/22 06:00 [entrez]
PHST- 2019/01/22 06:00 [pubmed]
PHST- 2019/01/22 06:01 [medline]
PHST- 2018/07/20 00:00 [pmc-release]
AID - S1319-0164(18)30159-2 [pii]
AID - 10.1016/j.jsps.2018.07.018 [doi]
PST - ppublish
SO  - Saudi Pharm J. 2019 Jan;27(1):49-55. doi: 10.1016/j.jsps.2018.07.018. Epub 2018 
      Jul 20.